NIH becomes latest agency to close the book on hydroxychloroquine
The hydroxychloroquine saga may finally be coming to an end.
Earlier this week, the Food and Drug Administration pulled its emergency use authorization for the drug, heavily touted by President Trump as a bulwark against the coronavirus. A couple of days later, the World Health Organization stopped its trial of the medication's effect on COVID-19 patients. Now, the National Institutes of Health have joined the consensus, halting its own clinical trial late Friday evening. NIH apparently agreed with the other agencies that the drug is "very unlikely" to benefit patients who require hospitalization.
Per Politico, this could be the drug's "death knell," at least in a certain respect. It's been around for decades and is approved to treat malaria, arthritis, and lupus, and doctors could still use it "off label" to treat coronavirus patients, but the end of the two major studies signal that scientists will focus elsewhere in the hopes of finding a breakthrough treatment for severely ill patients. Gilead's antiviral remdesivir and a cheap steroid called dexamethasone are promising contenders. Read more at Politico.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
2024: The year of conspiracy theories
IN THE SPOTLIGHT Global strife and domestic electoral tensions made this year a bonanza for outlandish worldviews and self-justifying explanations
By Rafi Schwartz, The Week US Published
-
Five medical breakthroughs of 2024
The Explainer The year's new discoveries for health conditions that affect millions
By Adrienne Wyper, The Week UK Published
-
Top films coming out in 2025
The Week Recommends Pick up some popcorn and settle in for a cinematic treat
By Adrienne Wyper, The Week UK Published
-
Honda and Nissan in merger talks
Speed Read The companies are currently Japan's second and third-biggest automakers, respectively
By Peter Weber, The Week US Published
-
Taylor Swift wraps up record-shattering Eras tour
Speed Read The pop star finally ended her long-running tour in Vancouver, Canada
By Peter Weber, The Week US Published
-
Drake claims illegal boosting, defamation
Speed Read The rapper accused Universal Music of boosting Kendrick Lamar's diss track and said UMG allowed him to be falsely accused of pedophilia
By Rafi Schwartz, The Week US Published
-
'Wicked' and 'Gladiator II' ignite holiday box office
Speed Read The combination of the two movies revitalized a struggling box office
By Peter Weber, The Week US Published
-
Jussie Smollet conviction overturned on appeal
Speed Read The Illinois Supreme Court overturned the actor's conviction on charges of staging a racist and homophobic attack against himself in 2019
By Peter Weber, The Week US Published
-
Quincy Jones, music icon, is dead at 91
Speed Read The legendary producer is perhaps best known as the architect behind Michael Jackson's 'Thriller'
By Peter Weber, The Week US Published
-
OJ Simpson, star athlete tried for murder, dead at 76
Speed Read The former football hero and murder suspect lost his battle with cancer
By Rafi Schwartz, The Week US Published
-
Momofuku's 'Chili Crunch' trademark uproar
Speed Read The company's attempt to own the sole rights has prompted backlash
By Rafi Schwartz, The Week US Published